[18F]FDG PET/CT as an endpoint marker in drug interventional studies in atherosclerosis - a structured review
Casper E W Gijsen, Felix M Mottaghy, Ahmed Tawakol, Joachim E Wildberger, Jan Bucerius · 2026
Read [18F]FDG PET/CT as an endpoint marker in drug interventional studies in atherosclerosis - a structured review by Casper E W Gijsen, Felix M Mottaghy, Ahmed Tawakol, Joachim E Wildberger, Jan Bucerius (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13542030.txt.
Description
Casper Gijsen and co-authors review drug trials that used FDG PET/CT scans as an endpoint marker in atherosclerosis. Inflammation helps start and worsen plaques in artery walls, and this scan can show and measure that activity in the body. The team gathered trials where change on the scan judged whether a drug worked.
Eighteen studies met their rules for full data work, drawn from a set they describe in the review. Ten looked at lipid-lowering drugs and the rest at new anti-inflammatory drugs. Statin therapies cut vessel FDG uptake in a more steady way than the new anti-inflammatory drugs did.
Catalog record
| CREATOR | Casper E W Gijsen, Felix M Mottaghy, Ahmed Tawakol, Joachim E Wildberger, Jan Bucerius |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |